Atara Biotherapeutics, Inc. (ATRA) has a consensus analyst rating of Hold, based on 13 analysts covering the stock. Of those, 3 recommend buying, 7 recommend holding, and 3 recommend selling.
The analyst consensus price target for ATRA is $15.50, representing a +195.8% upside from the current price of $5.24. Price targets range from a low of $6.00 to a high of $25.00.
